Making Virus Inactivation a Reality for Continuous Upscaled Processes
The Cadence™ Virus Inactivation (VI) system, a fully automated low pH virus inactivation system for both batch and continuous processing is one of the latest additions to Pall’s Continuous platform. This webinar will discuss how traditional low pH virus inactivation has been translated into an automatic system, and also the additional challenges associated with making it a continuous process. There will be a review of the two methods used for validating the design and an overview of the integration of capture chromatography and virus inactivation, which represents the first commercial scale combined unit operations in this space.
Moderator
David Johnson
Senior Global Product Manager, Continuous Purification
Pall Biotech
Speakers
Mark Schofield, Ph.D.
Principal R&D Engineer
Pall Biotech
Biography
Making Virus Inactivation a Reality for Continuous Upscaled Processes
Download our eBook on Virus Safety
Biotech | Pall Corporation webinar series
Integrity Assurance for Single-Use Systems An End-User’s Perspective
What should you consider when building an integrity control strategy for your single-use systems (SUS)? How do you overcome application challenges?
Join leading industry experts Charlotte Masy of GSK and Patrick Evrard from Pall Corporation to gain insights and answers in this webinar from BioPharma Asia on integrity Assurance for Single-Use Systems, an End-User’s Perspective. They will present several case studies to show how integrity concerns can be practically addressed for cGMP manufacturing applications and the results observed a few years on.
Attendees will learn about:
- The latest regulatory requirements for integrity assurance of SUS
- The different technologies available to control integrity of SUS
- Key parameters that affect integrity measurements
Register now for this webinar from industry experts on October 6.